PTC Therapeutics Announces Preliminary Financial Results and 2025 Guidance

PTC Therapeutics, Inc. recently issued an 8-K filing on January 13, 2025, revealing certain preliminary unaudited financial information for the fiscal year ending December 31, 2024. The company’s estimated total unaudited net revenue for the period is approximately $814 million. This includes anticipated unaudited net product revenue of about $601 million, with specifics such as unaudited net product revenue for Translarna™ (ataluren) at roughly $340 million and unaudited net product revenue for Emflaza® (deflazacort) at approximately $207 million. Moreover, royalty revenue associated with Evrysdi is expected to be around $211 million. It was emphasized that these figures are subject to finalization pending the completion of the company’s year-end audit.

In addition to the financial results, PTC Therapeutics also disclosed its financial guidance for the fiscal year ending December 31, 2025. The company foresees full-year total revenues ranging between $600 million and $800 million. This projection incorporates in-line products, potential new product launches, and anticipated royalty revenue from Evrysdi. Furthermore, the company provided insight into its anticipated GAAP Research and Development (R&D) and Selling, General, and Administrative (SG&A) expenses for the full year 2025. The GAAP expenses are expected to fall between $805 million and $835 million, with non-GAAP R&D and SG&A expenses projected to be in the range of $730 million to $760 million, excluding an estimated non-cash, stock-based compensation expense of $75 million.

During the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2025, at 2:15 p.m. EST, PTC Therapeutics will provide an update on its 2024 achievements, discuss forthcoming 2024 potential value-creating milestones, present preliminary 2024 unaudited financial results, and outline the 2025 financial guidance. The event will be webcast live on the Investors section of the company’s website. Following the conference, the company will observe an investor quiet period until its subsequent corporate update.

It is important to note that the information provided in the 8-K filing contains forward-looking statements and is not in accordance with Generally Accepted Accounting Principles (GAAP). These forward-looking statements involve risks and uncertainties that could result in actual results differing from these projections.

-END-

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read PTC Therapeutics’s 8K filing here.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.